Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Current Assets: 2017-2024

Historic Current Assets for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $1.4 billion.

  • Crinetics Pharmaceuticals' Current Assets rose 27.77% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 27.77%. This contributed to the annual value of $1.4 billion for FY2024, which is 139.55% up from last year.
  • According to the latest figures from FY2024, Crinetics Pharmaceuticals' Current Assets is $1.4 billion, which was up 139.55% from $574.2 million recorded in FY2023.
  • Over the past 5 years, Crinetics Pharmaceuticals' Current Assets peaked at $1.4 billion during FY2024, and registered a low of $177.5 million during FY2020.
  • Moreover, its 3-year median value for Current Assets was $574.2 million (2023), whereas its average is $764.9 million.
  • Data for Crinetics Pharmaceuticals' Current Assets shows a peak YoY soared of 139.55% (in 2024) over the last 5 years.
  • Crinetics Pharmaceuticals' Current Assets (Yearly) stood at $177.5 million in 2020, then surged by 94.22% to $344.7 million in 2021, then rose by 0.13% to $345.2 million in 2022, then surged by 66.33% to $574.2 million in 2023, then surged by 139.55% to $1.4 billion in 2024.